28 citations
,
December 2006 in “Clinical lung cancer” This review outlines various non-rash skin toxicities associated with novel targeted anticancer therapies and provides guidelines for their early diagnosis and management, but reports no new clinical results.
1 citations
,
October 2022 in “Дерматовенерология Косметология” This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.
3 citations
,
October 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.
9 citations
,
January 2021 in “Strahlentherapie und Onkologie” This case report suggests that topical St. John's wort oil may cause severe skin toxicity during radiotherapy for non-small cell lung cancer, acting as a significant radiosensitizer.